Atlas Blog

Expert-led insights on
FDA compliance

Insights on FDA inspections, compliance strategy, and regulatory intelligence from the Atlas team.

21 CFR 211.192 cover: 296 drug Form 483s cited weak investigations, with 41.2% of those inspections ending OAI against 18.8% without the citation.
CAPA & Quality Systems

21 CFR 211.192: production record review, what FDA cites, and what an investigation file needs

What 21 CFR 211.192 requires (quality unit review of production records before release, and a thorough, written investigation of any unexplained discrepancy that extends to other batches), what counts as an unexplained discrepancy, how FDA words 211.192 observations on Form 483s, which firms drew the citation in 2025 and 2026, how it relates to OAI outcomes, and what a defensible investigation file contains, from 302 observations on 296 drug inspections that closed January 2025 to October 2026.

Read more
The FDA inspection database is six sources, not one: where FDA publishes inspection outcomes, Form 483s, warning letters, import alerts and recalls, and how to join them by FEI number.
FDA Databases & Guidance

FDA inspection database: the six public sources of FDA inspection data, and how to join them

A guide to FDA inspection data as checked in November 2026: the six public sources (Data Dashboard inspections, the FOIA reading room, the warning letter page, Compliance Actions, import alert lists and recall enforcement reports), what each holds and lacks, what happened to the old Inspection Classification Database, and a five-step method for joining them for one facility by FEI number. Includes a worked example (Rohto-Mentholatum Vietnam, from Form 483 to warning letter in 2026) and Atlas counts of Form 483s issued in 2025 by product category.

Read more
FDA registration lookup cover: registered is not approved, with 9,901 registered drug FEIs and 221 OAI outcomes among registered facilities inspected since 2025.
FDA Databases & Guidance

FDA registration lookup: how to check a drug, device or food facility, and what registration proves

A guide to checking whether a company is FDA registered, as of November 6, 2026: the drug registration list (DECRS), the device Registration and Listing database, and food facility registration, which is not public. Covers what registration does and does not prove under 21 CFR 207.77 and 807.39, the renewal windows, and an Atlas join of FDA's November 6, 2026 drug registration file with FDA inspection classifications: 221 of 1,850 registered drug establishments inspected since January 2025 had an OAI outcome. Includes two worked examples that go from a registration hit to the facility's inspection record.

Read more
503B outsourcing facility: what FDA cites on 74 Form 483s at 18 facilities
FDA Databases & Guidance

503B outsourcing facility: definition, 503A vs 503B, and what FDA cites

A 503B outsourcing facility is a sterile compounder that registers with FDA and follows CGMP. This guide covers section 503B of the FD&C Act, registration, the FY2027 establishment fee and twice-yearly product reporting, a 503A vs 503B comparison, how to vet a 503B pharmacy, and the Atlas Form 483 record for 18 registered outsourcing facilities: 74 forms, 457 observations, the 21 CFR sections cited most, and the record of Leiters Health in Englewood, Colorado.

Read more
FDA Data Dashboard: six modules, FEI search and what it leaves out
FDA Databases & Guidance

FDA Data Dashboard: what each module shows, how to search it, and what it leaves out

A practical guide to the FDA Data Dashboard as checked on November 6, 2026: the six compliance dashboards and what each covers, how to look up a facility by FEI number, check a supplier's compliance history, export the data and call the API (endpoints, key, 5,000-row pages), how current each dataset is, and what the dashboard does not show (the observation narrative, investigator names, most Form 483 documents). Includes a comparison with FDA's FOIA reading room, the warning letter page and the Atlas directory, and one facility's citation history read across sources.

Read more
Gland Pharma FDA inspection history and the Dundigal Form 483 of October 2026
Company Inspection Histories

Gland Pharma FDA inspection history: the Dundigal 483, every facility and Cenexi

The FDA inspection record of Gland Pharma and its Cenexi subsidiary: nine facility records in India, France and Belgium, 48 inspections, 30 ending with a Form 483. What Gland disclosed about the October 2026 Form 483 at the Dundigal formulation facility in Hyderabad, what is not public yet, each facility's record, the sterile-processing citation FDA repeats across the group, and what happens next.

Read more
Granules India FDA inspection history and the Gagillapur Form 483 of October 2026
Company Inspection Histories

Granules India USFDA Gagillapur inspection: 11 observations and the full FDA record

The October 2026 USFDA inspection of Granules India's Gagillapur finished dosage facility ended with a Form 483 listing 11 observations. What Granules disclosed, how the shares moved, what happens next, the February 2025 warning letter it follows, and the full FDA record across ten Granules facility records: 41 inspections, 23 ending with a Form 483, including ten at Granules Pharmaceuticals Inc. in Chantilly, Virginia.

Read more